- Rating
- 3
- Confidence
- 3
- Informativeness
- 2
- Presentation
- 3
- Soundness
- 2
Read review
Paper summary
IgGM2 presents a unified all-atom diffusion framework for structure prediction and sequence–structure co-design of antibodies, nanobodies, and T-cell receptors. The model jointly generates CDR sequences and backbone conformations, followed by full-atom refinement. The authors demonstrate strong performance on immune-complex structure prediction and competitive results on CDR design benchmarks.
Critical strengths
The unified approach to sequence and structure generation is compelling, particularly its extension across antibodies, nanobodies, and TCRs. The structure prediction results are impressive, and the coordinated sequence–structure denoising strategy is technically interesting. The broad benchmarking provides encouraging evidence of the framework’s utility.
Critical weaknesses
My primary concern is that the structure prediction comparisons are not entirely equivalent, as IgGM2 can use fixed antigen structures and epitope information that are not provided to all baselines. Additionally, the design results rely entirely on computational metrics rather than experimental validation. While the generated structures appear promising, their functional performance remains uncertain.
Questions for authors
- How much of the improvement in structure prediction can be attributed to the model architecture versus the additional antigen and epitope information?
- Does joint all-atom generation provide meaningful advantages over conventional backbone generation followed by sequence design and structural relaxation?
3 comments
w2
We agree that experimental validation is important for assessing the functional performance of our designs. Our current evaluation relies on computational metrics and does not directly establish binding activity. We recognize this limitation and plan to seek experimental collaborations to validate representative designs on selected targets in future work.
q2
Directly demonstrating the advantages of joint all-atom generation over conventional design pipelines is challenging without experimental validation. We believe that joint all-atom generation can better capture sidechain interactions at the antibody–antigen interface. To evaluate this, we calculated shape complementarity (Sc) using PyRosetta, where higher Sc indicates better interface complementarity. All results were evaluated without FastRelax.
We first compared IgGM2-D with existing antibody design methods:
| Method | Mean Sc ↑ |
|---|---|
| DiffAb (HDOCK) | 0.4203 |
| AbX (HDOCK) | 0.4072 |
| dyMEAN | 0.1898 |
| IgGM | 0.3949 |
| RFAntibody | 0.2893 |
| IgGM2-D (switch=75) | 0.4700 |
IgGM2-D achieves the highest mean Sc (0.4700) among the compared methods.
We further compared single-phase generation (switch=200) and two-phase generation (switch=75), with and without sidechain packing.
| Sampling Strategy | Mean Sc ↑ |
|---|---|
| Two-phase (switch=75), generated sidechains | 0.4700 |
| Two-phase (switch=75), sidechain repacking | 0.4713 |
| Single-phase (switch=200), backbone only | 0.4002 |
| Single-phase (switch=200), sidechain packing | 0.4330 |
Sidechain packing improves single-phase Sc from 0.4002 to 0.4330, but it remains below two-phase generation (0.4700). Repacking the generated sidechains in the two-phase setting gives nearly identical Sc (0.4713 vs. 0.4700), suggesting that joint all-atom generation can capture more favorable interface interactions than conventional backbone generation followed by sidechain packing.
Dear Reviewer,
Thank you for your positive evaluation and constructive feedback. We would appreciate it if you could let us know whether our responses have addressed your concerns or if any further questions remain. Thank you!
w1/q1
We thank the reviewer for this question. Our comparison with conventional structure prediction methods is not strictly input-matched, as IgGM2-P uses additional antigen and epitope information. However, IgGM2 is designed for target-conditioned antibody and TCR prediction and design, where such information can be used to guide receptor generation, rather than predicting the entire complex from scratch.
To assess the contribution of conditioning information, we additionally evaluated IgGM2-P using AF3-predicted antigen structures, either predicted independently or extracted from predicted complexes, with and without epitope information. We also evaluated AF3 and Protenix v1 under a single-sample (1×1) setting, matching the sampling budget of IgGM2-P.
Epitope conditioning improves Mean DockQ from 0.498 to 0.604 and SR from 61.00% to 73.84% with native antigen structures. With predicted antigens and known epitopes, IgGM2-P achieves SRs of 51.16%–59.30%, exceeding the reported AF3 and Protenix v1 baselines. Without epitopes, its SRs of 46.51%–47.67% remain above their 1×1 results. These experiments also reveal sensitivity to antigen structural accuracy.
Beyond conditioning, we provide additional ablations supporting our training and modeling strategies.
1. Pretrained Initialization. We compared pretrained initialization with training IgGM2 from scratch on the cleaned 203-sample test subset.
Pretrained initialization substantially improves sequence recovery, DockQ, and IMP.
2. Shared Receptor Training. Due to computational constraints, we conducted this ablation using TCR–pMHC data. Both models inherit the same Protenix pretrained weights and are evaluated on 18 TCR–pMHC complexes.
Joint training improves DockQ from 0.5404 to 0.7461, supporting the benefit of learning across receptor types.
3. Noise-aligned Masking. We compared our masking strategy with MFDesign-style linear masking.
Noise-aligned masking improves structural and interface quality with comparable AAR.
Furthermore, IgGM2-P requires no MSA or multiple-candidate ranking. As reported in Table S2, its end-to-end runtime is approximately 14 seconds per complex, compared with approximately 30 minutes for AF3 under the evaluated protocol, including MSA generation.
Overall, these results support the contributions of both structural conditioning and our training and modeling strategies.